COMMUNIQUÉS West-GlobeNewswire

Calithera to Participate in Leerink Partners 7th Annual Global Healthcare Conference

09/02/2018 - 11:00

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced [...]

Ambu A/S: Articles of Association February 2018

09/02/2018 - 10:34

Articles of Association February 2018 Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/ef9a3672-1646-4832-92e3-9680a37d2a9a

Ambu A/S: Capital increase in connection with exercise of warrants

09/02/2018 - 10:22

In December 2014, Ambu A/S issued 2,000,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. These warrants were issued to 22 employees with a vesting [...]

BioPorto and Roche Diagnostics sign a distribution agreement for NGAL

09/02/2018 - 08:22

BioPorto A/S (“BioPorto”) has entered into a global distribution agreement with Roche, under which BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche’s cobas c 501/c 502 [...]

CellaVision AB Year-end Bulletin 2017

09/02/2018 - 08:21

Stable quarter with continued strategic initiatives October 1 - December 31, 2017 Net sales increased by 5 percent to SEK 76.1 million (72.8). Organic growth was 6 % (14). Operating profit increased to SEK 21.7 million [...]

NeuroSearch A/S releasing Annual Report 2017

09/02/2018 - 08:03

Announcement no. 1-18 Page 1 of 2 Company announcement 9 February 2018 The full version of the Annual Report 2017 for NeuroSearch is available in the enclosed PDF file. In 2017, NeuroSearch (NEUR) realised an operating [...]

iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference

09/02/2018 - 08:01

iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference Two Phase 1 trials to start in 2018 for A 2A receptor antagonist and [...]

NeuroSearch A/S releasing Annual Report 2017

09/02/2018 - 08:00

Announcement no. 1-18 Page 1 of 2 Company announcement 9 February 2018 The full version of the Annual Report 2017 for NeuroSearch is available in the enclosed PDF file. In 2017, NeuroSearch (NEUR) realised an operating [...]

Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial

09/02/2018 - 01:55

SYDNEY, Australia, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep” or the “Company”), announced today that the Database Safety Monitoring Board (“DSMB”) confirmed that the [...]

Pacific Biosciences Announces Outcome of First Phase of Patent Litigation Against Oxford Nanopore

09/02/2018 - 01:42

MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB ) announced today that the U.S. International Trade Commission (the “ITC”) has terminated its investigation [...]

miRagen Therapeutics, Inc. Prices Public Offering of Common Stock

09/02/2018 - 00:45

BOULDER, Colo., Feb. 08, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today [...]

FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.

09/02/2018 - 00:30

Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and [...]

Aclaris Therapeutics to Present Data on ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting

08/02/2018 - 23:44

ESKATA™ received FDA approval for the treatment of raised seborrheic keratoses (SKs) in December 2017 WAYNE, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led [...]

Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018

08/02/2018 - 23:25

TUCSON, Ariz., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. will host a conference call on Thursday, February 15, 2018 to review its fourth quarter and full-year financial results for 2017. President [...]

Chembio Diagnostics Announces Proposed Public Offering of Common Stock

08/02/2018 - 23:15

MEDFORD, N.Y., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ: CEMI ) (“Chembio”), a leader in point-of-care diagnostic tests for infectious diseases, announced today that it has commenced an [...]

Chembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial Results

08/02/2018 - 23:02

MEDFORD, N.Y., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ: CEMI ) (“Chembio”), a leader in point-of-care diagnostic tests for infectious diseases, announced today that it has won a three-year [...]

BioStem Technologies Adds Chief Revenue Officer to Executive Team

08/02/2018 - 23:00

Pompano Beach, FL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) – BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies [...]

Aduro Biotech to Present at the Leerink Partners 7th Annual Global Healthcare Conference

08/02/2018 - 22:31

BERKELEY, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO ) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the Leerink [...]

AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)

08/02/2018 - 22:30

BROOKLYN, N.Y., Feb. 08, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal [...]